Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Previously Published Works bannerUC San Diego

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.

  • Author(s): Doody, Karen M
  • Stanford, Stephanie M
  • Sacchetti, Cristiano
  • Svensson, Mattias ND
  • Coles, Charlotte H
  • Mitakidis, Nikolaos
  • Kiosses, William B
  • Bartok, Beatrix
  • Fos, Camille
  • Cory, Esther
  • Sah, Robert L
  • Liu-Bryan, Ru
  • Boyle, David L
  • Arnett, Heather A
  • Mustelin, Tomas
  • Corr, Maripat
  • Esko, Jeffrey D
  • Tremblay, Michel L
  • Firestein, Gary S
  • Aricescu, A Radu
  • Bottini, Nunzio
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458332/
No data is associated with this publication.
Abstract

Despite the availability of several therapies for rheumatoid arthritis (RA) that target the immune system, a large number of RA patients fail to achieve remission. Joint-lining cells, called fibroblast-like synoviocytes (FLS), become activated during RA and mediate joint inflammation and destruction of cartilage and bone. We identify RPTPσ, a transmembrane tyrosine phosphatase, as a therapeutic target for FLS-directed therapy. RPTPσ is reciprocally regulated by interactions with chondroitin sulfate or heparan sulfate containing extracellular proteoglycans in a mechanism called the proteoglycan switch. We show that the proteoglycan switch regulates FLS function. Incubation of FLS with a proteoglycan-binding RPTPσ decoy protein inhibited cell invasiveness and attachment to cartilage by disrupting a constitutive interaction between RPTPσ and the heparan sulfate proteoglycan syndecan-4. RPTPσ mediated the effect of proteoglycans on FLS signaling by regulating the phosphorylation and cytoskeletal localization of ezrin. Furthermore, administration of the RPTPσ decoy protein ameliorated in vivo human FLS invasiveness and arthritis severity in the K/BxN serum transfer model of RA. Our data demonstrate that FLS are regulated by an RPTPσ-dependent proteoglycan switch in vivo, which can be targeted for RA therapy. We envision that therapies targeting the proteoglycan switch or its intracellular pathway in FLS could be effective as a monotherapy or in combination with currently available immune-targeted agents to improve control of disease activity in RA patients.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item